Johnson & Johnson (JNJ): A Tier Three Dividend Growth Stock

When investors think about reliable dividend growth companies, few names carry the reputation of Johnson & Johnson.

Founded in 1886, Johnson & Johnson has spent more than a century building one of the most respected healthcare businesses in the world. Today, the company focuses on pharmaceuticals and medical technology, developing treatments and devices that help improve and extend lives across the globe. Its products address major healthcare areas including oncology, immunology, neuroscience, cardiovascular disease, and advanced surgical technologies. Because healthcare needs remain relatively consistent regardless of economic conditions, Johnson & Johnson benefits from a business model that tends to be more resilient than many other industries.

Key Statistics

• Ticker: JNJ
• Tier: Tier Three
• Industry: Healthcare
• Market Capitalization: Approximately $350 billion+
• Consecutive Years of Dividend Increases: 64 years
• Dividend King Status: Yes

Few companies can match Johnson & Johnson's dividend record. In 2026, the company announced its 64th consecutive annual dividend increase, placing it among the elite group of Dividend Kings that have raised dividends for more than fifty consecutive years.

Why JNJ Fits Tier Three

Within the DGI Crab framework, Tier Three investors are transitioning from pure growth toward a balance of growth and income.

The typical Tier Three target is a starting yield of roughly 4% to 5% combined with 4% to 5% annual dividend growth. While Johnson & Johnson's current yield may not always reach that exact target range, the company's dividend growth profile and exceptional reliability make it an ideal example of the type of business Tier Three investors should be studying.

What makes JNJ particularly attractive is its combination of stability and consistency.

Healthcare is not a cyclical luxury. People need medicines, surgeries, and medical devices regardless of whether the economy is booming or struggling. That creates a dependable stream of revenue that supports the company's dividend program.

Just as importantly, Johnson & Johnson has demonstrated its commitment to shareholders through recessions, inflationary periods, financial crises, and even a global pandemic. A company does not achieve 64 consecutive years of dividend increases by accident. That streak reflects a corporate culture that prioritizes both financial strength and shareholder returns.

For investors approaching retirement, reliability becomes increasingly valuable. The goal is no longer finding the fastest-growing company in the market. The goal is finding businesses capable of producing dependable and growing income for decades.

Johnson & Johnson excels in that role.

Final Thoughts from the DGI Crab

Johnson & Johnson may not be the most exciting stock in the market.

That's part of what makes it so attractive.

The company operates in essential healthcare markets, possesses one of the strongest balance sheets in corporate America, and has rewarded shareholders with more than six decades of consecutive dividend increases. For investors in the Tier Three stage of their journey, those characteristics are often more important than chasing the next hot growth story.

If I were building a Tier Three portfolio today, Johnson & Johnson would represent exactly the type of high-quality, sleep-well-at-night company that deserves serious consideration.